Dyadic International, Inc. (DYAI) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies.
Analysis Summary
Dyadic International, Inc. reported revenue of $1.2M in the most recent fiscal year, growing at a 5-year CAGR of -5.1%.
Trailing-twelve-month margins: gross margin 30.4%, operating margin -213.6%, net margin -219.5%.
At the current price of $0.40, DYAI has negative trailing earnings (P/E not meaningful) and an ROE of -29.18%. Market capitalisation stands at $15M.
Balance sheet quality for DYAI: current ratio of 2.7, net cash position of $2.3M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $0.40 |
| Market Cap | $15M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -6.38 |
| EV / EBITDA | -3.14 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -2918.10% |
| Return on Invested Capital | -278.95% |
| Return on Assets | -116.60% |
| Gross Margin | 30.44% |
| Operating Margin | -213.59% |
| Net Margin | -219.50% |
Financial Health
| Debt / Equity | -2.11 |
| Current Ratio | 1.65 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| DYAI | Dyadic International, Inc. | $15M | -29.2% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -47.31% |
| 3 months | -48.52% |
| Year-to-date | -57.17% |
| 1 year | -59.74% |
| 3 years | -78.12% |
52-Week Range
| 52-week High | $1.60 |
| 52-week Low | $0.34 |
| Avg Volume (90d) | 304K |
Related companies: ANVS · ATHE · BCAB · CELU · ELUT · MAIA · PYPD
Explore sector: Healthcare · Biotechnology
More sections of DYAI: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks